Schedule 14A Information
   Proxy Statement Pursuant to Section 14(a) of the Securities
                      Exchange Act of 1934

Filed by the Registrant  [ ]
Filed by a party other than the Registrant [x]

Check the appropriate box:
[ ]       Preliminary Proxy Statement
[ ]       Confidential, for Use of the Commission Only (as
          permitted by Rule 14A-6 (e)(2))
[X]       Definitive Proxy Statement
[ ]       Deifinitive Additional Materials
[ ]       Soliciting Materials Pursuant to ss.240.14a-11c or
          SS.240.14a-12



                         First Years Inc
        (Name of Registrant as Specified In Its Charter)

                        Phillip Goldstein
   (Name of Person(s) Filing Proxy Statement if other then the
                           Registrant)


           60 Heritage Drive, Pleasantville, NY  10570
   (914) 747-5262 // Fax (914) 747-5258 // oplp@optonline.net

I want to welcome you to the 2003 annual stockholders meeting of
The First Years.

We have one very important matter for you to vote on - the
election of three directors.
You will notice that there is only one nominee for each seat and
that each nominee is currently serving as a director.  That is
because the board has decided not to allow any other nominations.
We did that to make it easy for you to vote.  You see, if there
were more nominees than open seats, you might find it difficult
to decide whom to vote for and I am sure you have enough other
things to worry about.

Also, we have decided not to allow shareholders to present any
proposals at the meeting so as not to unnecessarily confuse you.
Be assured that we are always looking out for your best
interests.

Now, please cast your ballot and feel free to help yourself to
some refreshments.  Remember, your vote is very important.

                             *******
                                   May 1, 2003

Dear Fellow Stockholder of The First Years:

Does the above speech sound like something Big Brother, the
totalitarian leader of George Orwell's classic novel, 1984, would
say?  Well, I think it represents the views of Ronald J. Sidman,
the President, Chairman and Chief Executive Officer of The First
Years ("TFY").  Actually, Mr. Sidman is more like Big Daddy than
Big Brother.  What do I mean by that?  Please turn the page.




                      [PHOTO OF MR. SIDMAN]



Anyone who has met Ron Sidman can tell that he loves babies.
Unfortunately, he also seems to think that shareholders are as
incapable as babies when it comes to making decisions.
Therefore, they need Big Daddy, i.e., Ron Sidman to make those
decisions for them.  That is why he refuses to allow a
shareholder vote on the poison pill and wants to have a rigged
election for directors where the only nominees are the very
directors who adopted the pill in the first place.

Most shareholders want just one thing from their investment -- to
maximize the value of their shares.  A poison pill can harm
shareholders because it allows the board of directors, whose
interests are not the same as theirs, to prevent them from
accepting a premium offer for their shares.  As the head of TFY,
Ron Sidman earns a lucrative income in the form of salary,
bonuses, stock options and other perks.  In addition, several
members of his family are employed by TFY.  If TFY were sold,
some or all of them might be out of a job.  Yet, a poison pill
allows them to veto a proposed sale of TFY even if shareholders
overwhelmingly would prefer to sell.  Is that fair?

Here is a true story of how a poison pill cost shareholders of
another company many millions of dollars.  On October 26,1999,
Marc Shore, the CEO of Shorewood Packaging Corporation, called
Thomas Johnson, the CEO of Chesapeake Corporation, a competitor
of Shorewood and offered to acquire Chesapeake at $40 per share,
a 41% premium over Chesapeake's previous closing price of $28.38.
Johnson told Shore that Chesapeake was not for sale but that its
board would analyze the offer.  On November 18, 1999, Chesapeake
announced that its board of directors, in consultation with its
financial advisors, Goldman, Sachs & Co. and Donaldson Lufkin &
Jenrette, and its legal advisor, Hunton & Williams, carefully
considered Shorewood's unsolicited proposal and unanimously
concluded that it was "inadequate and not in the best interests
of Chesapeake's shareholders."  In response, Shorewood announced
that if Chesapeake's board would redeem its poison pill, it would
"move promptly to bring its proposal directly to Chesapeake's
stockholders."  Chesapeake's board, however, refused to redeem
its poison pill, thereby preventing shareholders from accepting
Shorewood's offer.  Today, 3-1/2 years later, Chesapeake's shares
are languishing at around $17.50 or 56% below Shorewood's $40
"inadequate" offer.

Could something like that happen to us?  With a poison pill in
place, it certainly could.  If we don't want end up like the poor
shareholders of Cheasapeake, we need to tell the board that a
poison pill is "inadequate and not in the best interests of our
shareholders" by returning the enclosed GREEN proxy card today.

When the board initially adopted the poison pill, it said that
"it is not intended to prevent a takeover of The First Years on
terms that are favorable and fair to all shareholders" and that
it is simply designed to prevent an acquirer from depriving
shareholders "of their ability to determine the destiny of The
First Years without paying or offering to pay fair value to all
shareholders."  That is just Newspeak to obscure the fact that
the poison pill shifts the power to ultimately determine "fair
value" from shareholders to Big Daddy Sidman and his family.

While any company's poison pill is worrisome, it is especially
important that TFY dismantle its pill.  One thing Mr. Sidman and
I agree on is that TFY stock is undervalued.  I firmly believe
that a sale of TFY to a larger strategic buyer, i.e., a company
in a similar or related business, is the most likely route to
maximizing shareholder value.  However, even if a strategic buyer
is willing to pay a sizeable premium to acquire TFY, a poison
pill could allow Mr. Sidman to veto such a sale.

Also, TFY has serious corporate governance problems.  Here is how
management's own proxy material puts it: "Evelyn Sidman is the
mother of Ronald J. Sidman and Kenneth R. Sidman. Benjamin Peltz
is the son-in-law of Mrs. Sidman and the brother-in-law of
Kenneth R. Sidman and Ronald J. Sidman."  With the board so
dominated by the Sidman clan, it is crucial that the poison pill
be dismantled.

In addition to dismantling the poison pill, I believe that at
least one director of TFY should have no ties to anyone named
Sidman.  Therefore, I intend to nominate Gerald Hellerman to
replace Evelyn Sidman, Ron and Ken's 89-year old mother.  (Mrs.
Sidman can contribute to TFY as a consultant.)  The most
important thing a director must do is critically evaluate the
CEO's performance.  The crisis of leadership in corporate America
has made it painfully clear that far too many directors of public
companies have failed to diligently fulfill their duty because
they were too chummy with the CEO they were supposed to monitor.
I don't think anyone can expect the CEO's mom to critically
monitor his performance.  I have served with Mr. Hellerman on
several boards and I am confident that he will have no problem
doing that.

Ron says he will not permit me to nominate Mr. Hellerman to
replace his mother or to present a proposal to dismantle the
poison pill.  I sincerely hope that he will change his mind and
allow democracy to prevail at the annual meeting.

Please sign and return the enclosed GREEN proxy card today.  If
you believe it may not be received before May 15th, you may fax
it to (631) 254-7622 (in addition to mailing it).  If you have
any questions, please call me at (914) 747-5262 or e-mail me at
oplp@optonline.net.

                                   Very truly yours,


                              Phillip Goldstein

PROXY STATEMENT IN OPPOSITION TO THE SOLICITATION BY THE BOARD OF

DIRECTORS OF THE FIRST YEARS, INC.



   ANNUAL MEETING OF STOCKHOLDERS (To be held on May 15, 2003)

 My name is Phillip Goldstein.  I am a shareholder of The First
    Years, Inc. (the "Company").  I am an investment manager
  presently managing investment portfolios with assets totaling
 more than $75 million.   I am sending this proxy statement and
the enclosed GREEN proxy card to stockholders of record on March
 20, 2003 (the "Record Date") of the Company.  I am soliciting a
     proxy to vote your shares at the 2003 Annual Meeting of
 Stockholders of the Company (the "Meeting") and at any and all
 adjournments or postponements of the Meeting.  Please refer to
     the Company's proxy soliciting material for additional
    information concerning the Meeting and the matters to be
    considered by the shareholders including the election of
                           directors.

This proxy statement and the enclosed GREEN proxy card are first
 being sent to shareholders of the Company on or about April 30,
                              2003.

                          INTRODUCTION

   There are two matters that the Company has scheduled to be
                   voted upon at the meeting:

  1 The election of three persons to serve as directors of the
  Company.

2 The ratification of the appointment of Deloitte & Touche LLP
  as independent accountants of the Company for the fiscal year
  ending December 31, 2003.

  In addition, I intend to introduce the following proposal at
                          the meeting.

  3 The Company's poison pill rights shall be dismantled.

 With respect to these matters, I am soliciting a proxy to vote
           your shares FOR the election of one nominee
 and FOR Proposals 2 and 3.

                    How Proxies Will Be Voted

All of the proposals scheduled by the Company to be voted upon at
 the meeting are included on the enclosed GREEN proxy card.  If
  you will not attend the meeting and you wish to vote FOR the
 election of my nominee and/or FOR my proposal, you may do so by
          completing and returning a GREEN proxy card.

   If you return a GREEN proxy card to me or to my agent, your
 shares will be voted on each matter as you indicate subject to
    the following condition: Ronald J. Sidman, the Company's
Chairman, President and Chief Executive Officer shall not prevent
the persons named as proxies from nominating Gerald Hellerman for
election as a director and presenting Proposal 3.  Mr. Sidman has
 advised me that he will not permit me to nominate Mr. Hellerman
 or present any proposal at the Meeting because I allegedly did
not give him sufficient advance notice of my intentions.  I have
     asked Mr. Sidman to waive the Company's advance notice
 requirement so that the shareholders can have an opportunity to
vote as they wish at the Meeting but thus far, he has refused to
   do so.  I believe that if a lawsuit is brought to order Mr.
   Sidman to count all the proxies, it could succeed.  I will
 continue to ask Mr. Sidman to permit me to vote all the proxies
as instructed but if he refuses, your shares may not be voted at
 the Meeting and I may consider other options including filing a
lawsuit to order the Company to count your votes and/or declining
   to attend the meeting which may prevent a quorum from being
                            reached.

Subject to the foregoing condition, in the event that you do not
 indicate how your shares are to be voted on a matter, they will
  be voted FOR the election of my nominee to the Board and FOR
Proposals 2 and 3.  If you return a GREEN proxy card, you will be
 granting the proxy holder(s) discretionary authority to vote on
 any other matters of which they are not now aware that may come
 before the meeting including matters relating to the conduct of
                          the meeting.


                       Voting Requirements

I do not intend to propose an adjournment of the meeting.  If an
adjournment is proposed, the proxy holder(s) will vote for or
against such adjournment in their discretion. Please refer to the
Company's proxy statement for the quorum requirements and the
voting requirements for each proposal it will present.  Proposal
3 requires a majority of the votes cast for approval.

                      Revocation of Proxies

You may revoke any proxy prior to its exercise by (i) delivering
a written revocation of your proxy at the meeting; (ii) executing
and delivering a later dated proxy to me or to the Company or to
our respective agents; or (iii) voting in person at the meeting.
  (Attendance at the meeting will not in and of itself revoke a
 proxy.) There is no limit on the number of times you may revoke
your proxy prior to the meeting. Only the latest dated, properly
                signed proxy card will be counted

        Information Concerning the Soliciting Shareholder

I, Phillip Goldstein, am the Soliciting Shareholder. My address
is 60 Heritage Drive, Pleasantville, NY 10570. I am an investment
manager who presently manages investment portfolios with assets
in excess of $75 million. Since December 1, 1992, I have been the
president and 50% shareholder of Kimball & Winthrop, Inc., the
general partner of Opportunity Partners L.P., a private
investment partnership. I am also the portfolio manager of
Opportunity Partners. Since 1996, I have taken an active role in
urging the management of other companies to take various actions
that I believe would benefit those companies and their
shareholders. My actions have included discussions with
management, submitting a shareholder proposal, conducting a proxy
contest and filing a lawsuit alleging breach of fiduciary duty.

I am deemed to be the beneficial owner of 143,710 shares of
Common Stock owned by my clients and me including -58,500 shares
owned by Opportunity Partners and 5,000 shares owned jointly by
my wife and me. All of our purchases of Common Stock have been
within the past two years.

                  REASONS FOR THE SOLICITATION

  Based on my own analysis of the Company's finances and growth
potential, I believe that the Company's stock is undervalued and
 that the Company could be sold at a significant premium to its
market value.  (Of course, there is no assurance of a sale or if
  it did, in what time frame.)  I also believe the poison pill,
which was adopted by the board without stockholder approval, is a
 serious impediment to such a sale.  Therefore, I wish to afford
shareholders an opportunity to (1) determine whether they want to
dismantle the Company's poison pill and (2) elect an independent
director who is committed to exploring all avenues of maximizing
shareholder value including a sale of the Company, to replace Mr.
                  Sidman's 89 year-old mother.

                      OTHER CONSIDERATIONS

 If my nominee is elected, there is no assurance that the entire
 board will agree to seek a sale of the Company.  In addition, a
  sale of the Company may require shareholder approval, and no
   assurance can be given that such approval will be obtained.
   Finally, various costs, including but not limited to those
related to holding a special meeting of shareholders, which would
be borne indirectly by shareholders, may be associated with such
  actions.  I believe that such costs are far outweighed by the
    benefit of a sale at a premium to the market price of the
                        Company's stock.

 I believe that all shareholders of the Company will benefit if
actions are taken to improve shareholder value.  However, I also
  have personal financial incentives to increase the Company's
stock price because my clients who hold shares of the Company pay
  me fees that are based upon the realized and unrealized gains
  that they earn.  Thus, these fees may partially depend on the
                 value of the Company's shares.

                PROPOSAL 1: ELECTION OF DIRECTORS

At the meeting, if permitted by Mr. Sidman, I will nominate the
following person for election as a director for a term expiring
in 2006.

Gerald Hellerman (Age 65), 10965 Eight Bells Lane, Columbia, MD
21044

Gerald Hellerman, 65, has been the principal of Hellerman
Associates, a financial and corporate consulting firm since he
founded the firm in 1993.  Present clients of Hellerman
Associates include the U.S. Department of Justice, and the
National Oceanic and Atmospheric Administration, a unit of the
U.S. Department of Commerce.  Mr. Hellerman has served as a
trustee or director of Third Avenue Value Trust from 1993 until
2002, and trustee of Third Avenue Variable Series Trust from 1999
until 2002.  Mr. Hellerman is a director and president of The
Mexico Equity and Income Fund, a position he has held since 2001.
He also serves as a director of Innovative Clinical Solutions,
Inc., and Frank's Nursery & Crafts, Inc. During March 2003 he was
elected a director and chairman of the board of meVC Draper
Fisher Jurvetson Fund I, Inc., and a director of Brantley Capital
Corporation.  During the past five years, he also served as a
director of Clemente Global Growth Fund, Inc.

Mr. Hellerman does not own any shares and he does not have any
arrangement or understanding with any person with respect to any
future employment by the Company or by any affiliate of the
Company.

The persons named as proxies on the enclosed GREEN proxy card
intend, in the absence of contrary instructions, to vote all
proxies they are entitled to vote IN FAVOR of the election of Mr.
Hellerman who has consented to stand for election and to serve if
elected. If Mr. Hellerman is unable to serve, an event not now
anticipated, the proxies will be voted for such other person, if
any, as is designated by the proxy holder(s).  In addition, I
intend to vote all GREEN proxies for the election of Walker J.
Wallace and Lewis M. Weston, who are management's nominees unless
you indicate that you wish to withhold authority to vote for
either or both of them but not to vote for Evelyn Sidman, the
remaining management nominee.  I have not requested permission to
name Walker J. Wallace and Lewis M. Weston in my proxy materials
nor have they granted me such permission.  You should refer to
management's proxy statement for information regarding the
qualifications and background of its nominees.  There is no
assurance that any of management's nominees will serve as
directors if my nominee is elected.

 PROPOSAL 2: RATIFICATION OF THE SELECTION OF DELOITTE & TOUCHE
          LLP AS INDEPENDENT ACCOUNTANTS OF THE COMPANY

In the absence of contrary instructions, the proxy holder(s) will
  vote your shares FOR this proposal.

  PROPOSAL 3: A STOCKHOLDER PROPOSAL TO DISMANTLE THE COMPANY'S
                              PILL

I think the best way to maximize shareholder value is to sell the
Company to a strategic buyer, i.e., one who is in a similar or
related business and that can realize synergies or reduce
overhead expenses in the combined company's operations. The
Company's board of directors has adopted a poison pill whose
purpose is to prevent shareholders from accepting a premium offer
for their shares unless the board approves it.  I do not think
the board should have a veto over the shareholders if they
determine that they wish to accept such an offer.  Therefore,
unless precluded from doing so by Mr. Sidman, I intend to
introduce a non-binding proposal recommending that the Company
dismantle its poison pill.   There is no certainty that the board
will implement this proposal if it is approved.   In the absence
of contrary instructions, the proxies will vote your shares FOR
this proposal.

                        THE SOLICITATION

     I am making this solicitation personally.  Persons
affiliated with or employed by affiliates of Opportunity Partners
may assist me in the solicitation of proxies.  They will not
receive any special compensation for their services.  Banks,
brokerage houses and other custodians, nominees and fiduciaries
will be requested to forward this proxy statement and the
enclosed GREEN proxy card to the beneficial owners of shares of
Common Stock for whom they hold shares of record.  I will
reimburse these organizations for their reasonable out-of-pocket
expenses.

     Initially, I will personally bear all of the expenses
related to this proxy solicitation.  Because I believe that the
shareholders will benefit from this solicitation, I intend to
seek reimbursement of these expenses from the Company.
Shareholders will not be asked to vote on the reimbursement of
solicitation expenses incurred by either the incumbent directors
or me. I estimate that my expenses will be about $15,000.  As of
April 30, 2003, my expenses have been approximately $ 6,500.

     There is no arrangement or understanding involving me or any
affiliate of mine that relates to future employment by the
Company or any future transaction with the Company.

                      ADDITIONAL PROPOSALS

     I know of no business that will be presented for
consideration at the meeting other than that set forth in this
proxy statement and in the Company's proxy statement.  Unless
instructed otherwise, if any other matters are properly presented
for consideration at the meeting, it is the intention of the
persons named as proxies in the enclosed GREEN proxy card to vote
in accordance with their own best judgment on such matters.

     DATED: April 30, 2003











                           PROXY CARD

 PROXY SOLICITED IN OPPOSITION TO THE BOARD OF DIRECTORS OF THE
FIRST YEARS, INC. BY PHILLIP GOLDSTEIN FOR THE ANNUAL MEETING OF
                  STOCKHOLDERS ON MAY 15, 2003

The undersigned hereby appoints Andrew Dakos, Rajeev Das, Steve
Samuels and Phillip Goldstein, and each of them, as the
undersigned's proxies, with full power of substitution, to attend
the Annual Meeting of Shareholders of The First Years, Inc. on
May 15, 2003, (the "Meeting"), and any adjournment or
postponement thereof, and to vote on all matters that may come
before the Meeting and any such adjournment or postponement the
number of shares that the undersigned would be entitled to vote
if present in person, as specified below.

(INSTRUCTIONS:Mark votes by placing an "x" in the appropriate [])

1. ELECTION OF THREE DIRECTORS

[ ]FOR GERALD HELLERMAN                  [ ] WITHHOLD AUTHORITY

Note:  It is intended that this proxy will be voted for the
election of Walker J. Wallace and Lewis M. Weston,
management's nominees (in addition to Mr. Hellerman) unless you
indicate that you wish to withhold authority to vote for either
or both of them by crossing out their name(s) in this sentence.
Permission has not been requested to name Walker J. Wallace and
Lewis M. Weston in the accompanying proxy materials nor have they
granted such permission.  There is no intention to vote this
proxy for any other management nominee.  Please refer to
management's proxy statement for information regarding the
qualifications and background of its nominees.  There is no
assurance that any of management's nominees will serve as
directors if Mr. Hellerman is elected.

2. RATIFICATION OF THE SELECTION OF DELOITE & TOUCHE LLP AS
INDEPENDENT ACCOUNTANTS

  FOR [   ]    AGAINST [   ]                   ABSTAIN [   ]

3.  A STOCKHOLDER PROPOSAL TO DISMANTLE THE COMPANY'S POISON PILL

  FOR [   ]    AGAINST [   ]                ABSTAIN [   ]

    Please sign and date below.  Your shares will be voted as
directed.  If no direction is made, this proxy will be voted FOR
 the election of the nominees named above in Proposal 1, and FOR
 Proposals 2 AND 3.  The undersigned hereby acknowledges receipt
of the proxy statement dated April 30, 2003 of Phillip Goldstein
 and revokes any proxy previously executed.  (Important - Please
                     be sure to enter date.)





 SIGNATURE (S) ________________________  Dated: _______________